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1ABSTRACT
Identification of genetic susceptibility loci for intestinal Behçet 
disease using a genome-wide association study
Yoon Suk Jung
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Jae Hee Cheon)
Several recent genome-wide association studies (GWAS) have 
identified susceptibility loci/genes for Behçet’s disease (BD). However, 
no studies have specifically investigated the genetic susceptibility loci 
associated with intestinal involvement in BD. We evaluated distinctive 
genetic susceptibility loci/genes associated with intestinal involvement 
in BD, which can be used to define intestinal BD.
GWAS was performed for 100 Korean BD patients without intestinal 
involvement, 99 with intestinal involvement, and 557 unaffected 
individuals. Candidate genes derived from GWAS were then validated 
using independent cohort samples from 138 patients without intestinal 
involvement and 196 patients with intestinal involvement. 
Immunohistochemistry, real-time polymerase chain reaction, enzyme-
linked immunosorbent assay, western blot, and gene silencing were 
performed to evaluate functional gene expression in intestinal epithelial 
cells and in human and murine colon tissues.
GWAS and validation studies showed intestinal BD-specific 
2association with the NAALADL2 gene (rs3914501, OR = 1.914, P = 3.5 
× 10−4) and YIPF7 gene locus (rs6838327, OR = 1.567, P = 3.4 × 10−4). 
Haplotype analysis was suggestive of associations between DCAF12, 
IL10, NAALADL2, PLCB1, SCHIP1, and TGFBR3 with intestinal BD 
and its disease phenotype. The results suggest that these genes are 
potentially causal variants in association with intestinal BD. Gene 
functional and pathway analyses indicated that intestinal BD shares 
inflammatory pathways with inflammatory bowel disease (IBD). 
NAALADL2 and YIPF7 displayed exacerbated inflammatory responses 
in vitro and in vivo. 
In conclusion, our GWAS results separating between intestinal BD 
and BD without intestinal involvement enable a more comprehensive 
analysis of disease specificity and provide insight into the common and 
different pathogenic mechanisms for intestinal BD and IBD
--------------------------------------------------------------------------------------
Key words : Intestinal Behçet’s disease, genome-wide association study, 
pathway analysis, disease susceptible gene
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Yoon Suk Jung
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Jae Hee Cheon)
I. INTRODUCTION
Behçet’s disease (BD) is a rare chronic, inflammatory, and multi-systemic 
disorder characterized by recurrent oral and genital ulcers, ocular lesions, skin 
manifestations, arthritis, and vascular, neurological, and intestinal 
involvement,1-3 which is prevalent in countries along the old silk route 
spanning from Far East Asia to the Middle East and the Mediterranean basin. 
Multiple factors including undefined components of the environment and host 
genetic changes interact cooperatively to develop the disease,1-3 Although the 
nature of these genetic variants remains unknown for the most part, numerous 
genetic risk factors are thought to contribute to the disease susceptibility,2-5 In 
4addition to human leukocyte antigen gene encoding B*51 (HLA-B*51) and 
regions encompassing the major histocompatibility complex (MHC) class I,
GWAS studies have reported several other BD susceptible non-HLA loci and 
genes including interleukin (IL) 10, IL 23 receptor (IL23R)-IL 12 receptor 
beta 2 (IL12RB2), the C-C chemokine receptor 1 gene (CCR1), signal 
transducers and activators of transcription (STAT4), genes encoding the killer 
cell lectin-like receptor family members (KLRC4-KLRK1), and the 
endoplasmic reticulum aminopeptidase gene (ERAP1). 2-6
Intestinal BD (BD with intestinal involvement) is diagnosed if there is a 
typically shaped ulcer in the gastrointestinal tract and clinical findings meet 
the diagnostic criteria for BD.7 Interestingly, intestinal BD is rare in 
Mediterranean BD patients (0 to 3%),8, 9 whereas it is relatively frequent in 
East Asia, including Korea and Japan (5-25%).10-12 Given these geographic 
and racial differences in incidence of BD with or without intestinal 
involvement, intestinal BD is likely to have distinguishable pathogenic 
pathways from BD without intestinal involvement and there may be 
distinctive genetic susceptibility loci specifically associated with intestinal BD.
Moreover, some phenotypic overlaps (inflammation in the eyes, skin, and 
intestine), shared genetic associations in the MHC class I region, IL10, and 
IL23R and the effectiveness of tumor necrosis factor (TNF)-α blockade 
therapy implicate common pathogenic pathways between BD and 
inflammatory bowel disease (IBD).13, 14 In particular, given that IBD and 
5intestinal BD share a number of clinical phenotypes in terms of intestinal 
manifestations, therapeutic applications, and clinical courses,14 there may be a 
shared inherited susceptibility between intestinal BD and IBD. Otherwise, 
intestinal BD and IBD are considered two distinct diseases and thus there may 
be specific genetic markers for intestinal BD, but not for IBD. Although 
through several recent GWAS studies investigating BD patients, much is now 
known about genetic susceptibility loci associated with BD development,2-6
all of these studies have focused on BD itself and exploring genetic factors 
associated with intestinal involvement of BD has not been challenged to date
because of its rarity. 
In the current study, we assessed specific genetic susceptibility loci 
associated with intestinal BD using a GWAS in the Korean population, which 
might define specific genetic markers for intestinal involvement of BD. We 
also investigated the functional consequences of the genetic factors 
influencing both the disease susceptibility and phenotypes of BD with or 
without intestinal involvement.
II. MATERIALS AND METHODS
1. Study subjects and DNA Extraction
A total of 533 BD patients of Korean descent, including 238 BD cases 
6without intestinal involvement and 295 with intestinal BD cases were enrolled 
in the Behçet’s disease clinics of Yonsei University College of Medicine, 
Severance Hospital, Seoul, Korea between June 2006 and August 2013. 
Intestinal BD was diagnosed according to the established criteria based on 
colonoscopic features and clinical manifestations.7 Only patients who were 
finally classified as “definite” or “probable” types were included in this study.
The demographic and clinical characteristics of the study subjects are 
summarized in Supplementary Table 1. We obtained the genotyping results in 
randomly selected 600 individuals matched up sex with the cases from 10,000 
healthy Koreans belonging to the Korean Association Resource Project using 
the same platform. This study was approved by the Institutional Review 
Boards of Severance Hospital, Yonsei University and all patients and controls 
provided a written consent. Genomic DNA was extracted from the whole 
blood samples using the DNA blood maxi kit from Qiagen (Santa Clarita, CA, 
USA).
2. Genotyping and quality control in GWAS.
A total of 199 patients with BD (100 BD patients without intestinal 
involvement and 99 with intestinal BD) entered into genotyping using 
Affymetrix Whole-Genome-Wide Human SNP Array 6.0. (Affymetrix, Santa 
Clara, CA, USA), in which all samples showed call rates of > 95% finally 
entered into case–control analysis. After excluding controls with < 95% call 
7rates, mismatched sex, and subjects who were the potential relatives, a total of 
557 control samples of 600 Korean individuals entered into case–control 
analysis. 
In quality controls, SNPs showing P value > 1 ´ 10-4, if they were not 
mapped to autosomal chromosomes in cases or controls, those showing < 1% 
minor allele frequency, or those showing P value < 1 ´ 10-7 Hardy-Weinberg 
equilibrium (HWE) in controls were excluded from the analysis. The 
quantile–quantile plot (Q–Q plot) was obtained to evaluate the overall 
significance of the genome-wide associations and the potential impact of 
population stratification. After quality control and filtering processes, 
genotype data for 651,605 SNPs in all BD patients (BD with and without 
intestinal involvement) vs. healthy controls, 646,355 SNPs in BD patients 
without intestinal involvement vs. healthy controls, 652,294 SNPs in 
intestinal BD patients vs. healthy controls excluding SNPs significant in BD 
patients without intestinal involvement, 637,816 SNPs in patients with 
intestinal BD patients vs. BD patients without intestinal involvement were 
used for the final GWAS analysis.
Principal component analysis (PCA) was used to assess the population 
structure stratification using the software package EIGENSTRAT v.5.0.115
with default parameters. For the initial PCA, our Korean samples (199 cases 
and 597 controls) were analyzed along with unrelated European (CEU) and 
African (YRI) individuals obtained from 1000 Genomes Project 
8(phase1_release_v3.20101123) using 391,001 markers which showed > 95% 
call rates, > 5% MAF, and > 0.05 HWE P value. In addition, 199 BD cases 
were compared with 597 controls. We generated a Manhattan plot of −log10 P
using Haploview (V.4.2) (http://www.broadinstitute.org/haploview).
3. Imputation
Aiming to increase our coverage of common variants and capture additional
association signals in our study, missing genotypes were imputed in 1000 
Genomes Project data released March 2012 (Phase I, version 3) as the 
reference using IMPUTE (v.2.0)
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html). Reference haplotypes 
included data from 246 African, 181 American, 286 Asian, and 379 European 
individuals because combination panel may improve imputation 
performance.16 A total of (5,418,765) SNPs with an estimated imputation 
accuracy of > 0.9 and minor allele frequency (MAF) of > 0.01 were included 
in the association analysis.
4. SNP Selection and Validation Study
Following the genome-wide discovery analysis, 47 SNPs (25 loci) from 
regions containing more than 2 SNPs of P value < 1 ´ 10-4 within 100 Kb or 
lowest P value in our GWAS and 13 SNPs (8 loci) previously reported SNPs 
in association with BD were selected for the replication study in a non-
9overlapping set of 295 intestinal BD and 238 BD without intestinal 
involvement, and 391 controls for whom DNAs were available.
The validation of rs17856199, rs1800871, and rs4500591 was performed 
using TaqMan genotyping assays (Applied Biosystems, CA, USA) and the 
validation of the others was performed using BioMark TM HD system 
(Fluidigm, CA, USA) according to the manufacturer’s protocol and 
recommended quality control measures. The concordance rate in 44 SNPs 
among duplicated samples between Affymetrix Whole-Genome-Wide Human 
SNP Array 6.0 and TaqMan genotyping assays or BioMark TM HD system 
was > 99.9%, indicating a negligible possibility of genotype error.
5. Haplotypic Analysis
To clarify the susceptibility region and narrow down the candidate region, 
haplotypic associations were analyzed using a method developed by Lake et 
al.17 The method is implemented in R (http://www.r-project.org) and provides 
estimates and the significance of the relative effects of haplotypes on the trait 
compared to the effects of the baseline haplotype. In this study, a haplotype 
consisting of a combination of the major alleles from each locus was used as a 
baseline.
6. In silico analyses of SNP functions
For the Cis- expression Quantitative Trait Locus (cis-eQTL) analysis for 
10
revealing the genetic loci in the control of specific changes in gene expression,
we looked the publicly available sources from eQTL Browser 
(http://www.sanger.ac.uk/ resources/software/genevar/). The cis associations 
of each SNP and its proxies with the expression of nearby genes were 
searched in fibroblasts, lymphoblastoid cells, T-cells, and tissues from adipose 
and skin.18, 19
Regulatory SNPs were surveyed using RegulomeDB20
(http://regulomedb.org) and HaploReg v2 resource 
(http://compbio.mit.edu/HaploReg). Variants in RegulomeDB analysis can be 
classified into one of six RegulomeDB categories with scores ranging from 1 
to 6 indicating putative functions and a total of 45 SNPs were used for the 
functional annotation analysis of established prostate cancer risk alleles. The 
HaploReg analysis was used to identify biological features in sequences 
containing the BD risk variants and SNPs in high LD (r2 0.8 in Europeans 
from the 1000 Genomes Project) and evolutionarily conserved regions based 
on SIte-specific PHYlogenetic (SiPhy) analysis.21, 22 Functional elements 
located in the same regions as index and the correlated SNPs were identified
in ENCODE23 and annotated with potential effects on regulatory motifs based 
on existing databases such as TRANSFAC, JASPAR, and PBMC.22 In 
HapoReg analysis, we selected ASN (CHB+JPT) as the population for LD 
calculation, and we chose all SNPs in the ASN population as the background 
for enhancer enrichment analysis.
11
Prediction of the possible impact of an amino acid substitution on protein 
function was done by using SIFT (Sorting Intolerant From Tolerant, 
http://siftdna.org/www/SIFT_dbSNP.html) or polymorphism phenotyping v2 
(PolyPhen-2) algorithms, http://genetics.bwh.harvard.edu/pph2), in which 
“Damaging” or “Probably/Possible damaging” were considered to predict an 
effect on protein function, respectively.
7. Immunohistochemical staining
For immunohistochemical analysis, formalin-fixed paraffin-embedded 
(FFPE) tissue sections (21 normal tissues obtained from cancer patients and 
28 inflamed tissues from intestinal BD patients after surgical resection were 
deparaffinized, washed with distilled water, and heated in 10 mM citrate 
buffer (pH 6.0) for 10 min for antigen retrieval. Sections were then washed 
with distilled water and treated with 3% H2O2 for 5 min. After washing with 
Tris-buffered saline containing 0.1% Tween-20 (TBS-T), sections were 
blocked with 2.5% normal horse serum in TBS-T for 1 h and then incubated 
with NAALADL2 antibody (1:100, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) and YIPF7 (1:100, Novus Biologicals, Littleton, CO, USA) diluted
in 1% normal horse serum at 4°C overnight. After washing, sections were 
incubated with biotin-conjugated IgG (1:500, Vector Laboratories, 
Burlingame, CA, USA) and then treated with reagents from a Vecta-Elite 
streptavidin-peroxidase kit (Vector Laboratories) with a benzidine substrate 
12
for color development. Sections were counterstained with diluted hematoxylin 
and examined by light microscopy (Olympus BX41; Olympus Optical, Tokyo, 
Japan). To quantify gene expression, we studied randomly selected fields for 
each sample at 100× magnification and scored ranging from 0 to 3.
8. Cell culture, treatment, and enzyme-linked immunosorbent assay 
(ELISA)
The HT-29 cell line (Korean Cell Line Bank, Seoul, Korea) was maintained 
at 37℃ in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% heat-inactivated fetal bovine serum (FBS) and 1% antibiotics in a 
humidified atmosphere of 5% CO2. Cells were incubated with LPS (1 μg/mL) 
for the indicated time.
Knockdown of a specific gene was achieved by 24 h transfection of siRNA 
or non-targeting control (AccuTarget, Bioneer, Daejeon, Korea) into HT-29 
cells. To assess inflammatory response, cell culture medium was replaced 
with medium containing LPS (1–2 μg/mL) at 24 h post transfection and 
harvested at 3 h for qRT-PCR analysis, 24 h for immunostaining, and at 72 h 
for ELISA after LPS-treatment. ELISA was performed using BioLegend 
human TNF-α ELISA MAXTM kit (Biolegend, San Diego, CA, USA). 
9. Quantitative Real-time Reverse-transcription Polymerase Chain 
Reaction (RT-PCR)
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Total RNA was extracted using TRIzol Reagent (Life Technologies, Grand 
Island, NY, USA) and RNA was reverse-transcribed using SuperScript First-
Strand Synthesis kit (Life Technologies) according to the manufacturer-
recommended protocol. The cDNAs were mixed in triplicate using SYBR 
Green master mix (Life Technologies) and pairs of primers (4 pmol of each 
primer). PCR was done using primers for NAALADL2, YIPF7, TNF-α, IL12B, 
and IL22 (AccuTarget qRT-PCR primer, Bioneer). Samples were amplified in 
a StepOne Plus real-time PCR system (Applied Biosystems) for 40–45 cycles 
using the following PCR variables: 95℃ for 30 sec, 60–62℃ for 30 sec, and 
72℃ for 40 sec. Finally, quantitative analysis was performed using the 
relative standard curve method and the results were reported as the relative 
expression or fold change compared to the calibrator after normalization of 
the transcript level to the endogenous control, GLYCERALDEHYDE-3-
PHOSPHATE DEHYDROGENASE (GAPDH) or β- ACTIN (β-actin).
10. Trinitrobenzenesulfonic acid (TNBS)-induced colitis of mice
We used 8-week-old male C57BL/6 (Orient, Seongnam, Korea). The mice 
were maintained on a 12:12-hour light:dark cycle under specific pathogen-
free conditions. Mice were slightly anesthetized with an i.p. injection of 
zoletil (20 mg/kg) and xylazine (10 mg/kg). Colitis was induced by the 
administration of 5% (w/v) TNBS solution (100 µl) in 50% ethanol into the 
colon of lightly anesthetized mice via a thin round-tip needle equipped with a 
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1-mL syringe inserted into the colon 4 cm proximal to the anus. The animals 
were kept in a head-down vertical position for 2 min to distribute the agents 
within the entire colon and caecum (day 0). Throughout the experiment, mice 
were monitored for body weight loss and overall mortality. At day 3, the mice 
were sacrificed and the colon was quickly removed from the proximal rectum, 
close to its passage under the pelvisternum, opened longitudinally and gently 
cleared of stool by PBS. The colon length was measured between the ileo–
cecal junction and the proximal rectum. The colon tissue was then used for 
histological and qRT-PCR analysis.
11. Network and pathway analyses 
We analyzed the biological pathways using Ingenuity Pathway Analysis 
(IPA, ver 23814503, http://www.ingenuity.com/) to evaluate whether these 
subnetworks are biologically meaningful via comparing the functional 
relationship between the constituent genes from GWAS. Gene lists from our 
study and ‘Reported Gene’ lists from GWAS Catalog 
(www.genome.gov/gwastudies) were entered into the IPA database. The 
network score or P value represents the significance of the focus gene 
enrichment and enrichment of focus genes to diseases and functional 
categories was also evaluated in the IPA Knowledge Base.
12. Statistical Analysis
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The association of the selected SNPs with the disease or a subset of the 
disease was analyzed by comparing minor allele frequencies between case and 
control groups, with a statistical significance determined by chi-square test, 
Cohchran-Amitage Trend test (for a codominant model) as parametric 
methods, and Jonckheere-Terpstra test as a non-parametric method (data not 
shown) using SAS 9.1.3 version (SAS institute Inc. Cary NC, USA). Also, a 
logistic regression analysis was used to obtain the odds ratio (OR), 95% 
confidence interval (CI) for OR, and corresponding P values comparing cases 
with controls regarding the selected SNPs under four alternative models 
(dominant, recessive, codominant, and allelic). Significant P values in 
association analysis were computed for the replicated samples using the 
Cochran–Armitage trend test as well as for the combined samples using the 
Cochran-Mantel-Haenszel test (the Bonferroni correction was applied with 
statistical significance level P < 2.0 × 10−3 for 25 genes). For minor allele 
frequency of 0.4, our study achieved 80% power to detect OR as small as 1.56, 
which was estimated by Quanto (version 1.2.4). For each reported SNP, the 
power for detection at a nominal P value of 0.05 was calculated based on the 
reported OR and the allele frequency in the Korean population (from the 
current study).
The prognosis of intestinal BD (the cumulative probabilities of operation, 
admission, corticosteroid use, and immunosuppressant use after diagnosis) 
were analyzed using the Kaplan–Meier method, with differences determined 
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using the log-rank test. Student’s t-test and Kruskal-Wallis test were used to 
compare the differences between sample groups in vitro and in vivo, 
respectively and p-values < 0.05 were considered statistically significant.
III. RESULTS
1. GWAS and SNP selection for candidate genetic markers of BD 
A total of 199 patients with BD (100 BD without intestinal involvement, 99 
with intestinal involvement; intestinal BD) and a total of 557 controls with 
call rates of > 95% in GWAS entered into the case–control analysis. An 
overview of the clinical characteristics of study samples is provided in 
Supplementary Table 1. The PCA results suggest a low possibility of false-
positive associations resulting from the population admixture (Figure 1A)
similar with previous Korean IBD GWAS data.24, 25 There was a moderate 
variance between BD cases and controls subjects in our data set on 
eigenvectors 2, suggesting the genetic heterogeneity arising from the disease 
(Figure 1B).
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Table 1. Clinical and demographic characteristics of BD without intestinal 
involvement and intestinal BD patients
BD without intestinal 
involvement (n=238)
Intestinal 
BD (n=295)
Sex, male (%) 62 (26.1) 135 (45.8)
Mean age (years) 41.8±11.8 44.3±12.3
Mean age at diagnosis (years) NA 40.1±11.8
Mean disease duration (years) NA 7.5±5.7
HLA-B51 positivity (%)a 83 (36.7) NA
Clinical manifestations (%)
  Oral ulcers 238 (100) 273 (92.5)
  Genital ulcers 212 (89.1) 154 (52.2)
  Eye lesions 76 (31.9) 52 (17.6)
  Skin lesions 219 (92.0) 192 (65.1)
  Arthritis/arthralgia 134 (56.3) 158 (53.6)
  Vascular lesions 10 (4.2) 11 (3.7)
  Central nervous system lesions 5 (2.1) 5 (1.7)
  Epididymitis 3 (1.3) 0
Intestinal complications (%)
  Perforation NA 28 (9.5)
  Fistula NA 26 (8.8)
  Stricture NA 25 (8.5)
  Abscess NA 13 (4.4)
Medication use (%)
  5-aminosalicylic acid/ sulfasalazine NA 288 (97.6)
Corticosteroids NA 136 (46.1)
Azathiopurine/6-mercaptopurine NA 107 (36.3)
Anti-TNF agent NA 8 (2.7)
BD, Behcet’s disease; HLA, human leukocyte antigen; TNF, tumor necrosis 
factor; NA, not applicable
a Data is available in 226 patients with systemic BD 
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Figure 1. Principal components analysis (PCA). (A) PCA of All participant 
samples (199 BD case and 597 control) along with reference samples from 
1000 Genomes Project. BD cases are shown in red, controls in green, Utah 
residents with ancestry from northern and western Europe (CEU) in purple, 
and Yoruba in Ibadan, Nigeria (YRI) in dark blue. (B) PCA of 199 BD case 
and 597 control samples without samples from 1000 Genomes Project. BD 
cases are shown in red and controls in green.
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After SNP data quality control, we analyzed the association between all BD 
(intestinal BD+BD without intestinal involvement) and controls for assuming 
total BD risk, which showed only one significant SNP (rs1681595 in 
noncoding region) after multiple test correction. Additionally, we tried to 
analyze subgroups to examine disease phenotypes minutely, for we assumed 
that intestinal BD is another disease originated from polygenic and differently 
affected factors different from BD without intestinal involvement. Of these 
SNPs of P < 1.0 × 10−4, 5 non-clustered SNPs were detected from 
comparisons between intestinal BD and BD without intestinal involvement 
among BD-specific 218 SNPs after Bonferroni correction, of which one SNP 
(rs1681595) with lowest P value and 2 genomic loci (rs4500591 in 
MIR548F5/NBEA and rs32019 in CD180) were subjected to validation test. 
Moreover, we directly compared intestinal BD with BD without intestinal 
involvement and 108 significant SNPs were obtained before the multiple test 
correction, even though we did not detected any significant SNPs after the 
correction. Of these SNPs, one SNP (rs6838327 in YIPF7) with lowest P
value in clustered genomic locus was subjected to validation test. Additionally, 
we tried to compare disease groups with healthy control group to explore 
factors further affecting intestinal BD. Consequently, there were newly 
identified 6 clustered SNPs including 2 genomic loci (LOC284395, 
CD300LB) after multiple test correction among significant 342 SNPs 
including PSORS1C1 loci in comparison between BD without intestinal 
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involvement and healthy control. To assess intestinal BD-associated SNPs, we 
compared intestinal BD with healthy control with 60,137 SNPs not included 
in regions of BD without intestinal involvement to exclude factors related BD 
without intestinal involvement, which enable more comprehensive analyzing 
disease subtypes at the genome-wide level in consideration of polygenic 
factors that does not acting alone or non-sequencial or independent risk 
factors. This analysis identified 5 non-clustered SNPs including a genomic 
locus after multiple test correction. Thus, we selected additionally clustered 
genomic loci with more than 4 SNP among significant 319 SNPs before 
multiple test as well as non-clustered SNP with lowest P value (rs4500591 in 
MIR548F5/NBEA). 
To improve the coverage of variants specifically associated with intestinal 
BD, we imputed missing genotypes of autosomal SNPs in our GWAS 
collection of 99 intestinal BD cases and 557 controls using 1000 Genomes 
Phase I integrated variant set, from which CD300C/CD300LB (P < 2.0 × 10-6) 
and TNFRSF13B (P < 2.5 × 10-6) on chromosome 17 showed significant 
associations with intestinal BD development. 
Following the genome-wide association screening, the 47 selected SNPs 
were underwent a replication and validation study using additional 
independent 196 patients with intestinal BD, 137 patients with BD without 
intestinal involvement, and 391 controls to evaluate the genome-wide 
association screening. The workflow of this study, Manhattan plots, and 
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regional association plots that provide a detailed overview of the associated 
regions is given in Figure 2–4, respectively.
Figure 2. Workflow of the study. 
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Figure 3. Manhattan plot from comparison between intestinal BD vs. healthy 
control (A), comparison between BD without intestinal involvement vs. 
healthy control (B), comparison between intestinal BD vs. BD without 
intestinal involvement (C), comparison between all BD vs. healthy control (D), 
and imputated comparison between intestinal BD vs. healthy control (E). (F) 
Cluster plot of assay of rs1681595 from panel (A). Blue line indicates P < 10-4, 
brown line P < 10-7, and red line P < 10-5.
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Figure 4. Regional association plots from GWAS (−log10 P values; top) and 
gene loci (bottom). (A) rs3914501 (intestinal BD vs. healthy control), (B) 
rs6838327 (BD without intestinal involvement vs. intestinal BD), (C) 
rs4959053 (BD without intestinal involvement vs. healthy control). Single 
nucleotide polymorphisms (SNPs) are plotted using the estimated 
recombination rates from hg19/1000 Genomes Asian groups (December 2012). 
The validated SNPs and the −log10 P values were shown by pink circles and 
red asterisk. Plots were generated using LocusZoom.
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2. Replication study for genotype validation for intestinal involvement of 
BD
The results of 47 selected SNPs from 25 loci showing the strongest 
association signals or a significant association in more than two regions in at 
least one of the segmented analyses, 13 SNPs from previously identified 8 
gene loci by the BD GWAS studies (rs12119179 and rs1495965 in IL23R-
IL12RB2; rs1554286, rs1518111, rs1800871 in IL10; rs5742906 in CCR1-
CCR3; rs17482078, rs2927615 in ERAP1; rs4713242 in HLA-F-AS1–HLA-A; 
rs2255336 in KLRC4-KLRK1; rs12525170, rs4959053 in PSORS1C1; 
rs7574070 in STAT4),2-6, 26 and one locus (rs61730133 in CD300C/CD300LB) 
from our imputed data are selected for the replication study. 
Of the selected 43 SNPs, non-clustered SNPs and imputed SNP showed no 
genetic variation in our study. The comparison between intestinal BD and BD 
without intestinal involvement showed only one intestinal BD-specific 
association of YIPF7 gene locus on chromosome 4 (rs6838327, OR = 1.567, P
combined = 3.4 × 10−4 in an allelic model) after Bonferroni correction 
calculated as 0.05/25 tests (Table 2). In addition, a NAALADL2 locus on 
chromosome 3 (rs3914501, OR = 1.914, P combined = 3.5 × 10−4 in a 
recessive model) showed significant association between intestinal BD and 
healthy control (Table 3), and modest evidence of association (rs16848171, 
OR = 3.208, P combined = 5.0 × 10−3 in recessive model before Bonferroni 
correction) between intestinal BD and BD without intestinal involvement but 
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no association between BD without intestinal BD and healthy control 
(Supporting information 4). PSORS1C1 gene locus (rs12525170) nearby 
HLA-B on chromosome 6 showed a significant association with BD without 
intestinal involvement (OR = 1.606, P = 1.1 × 10−5 in a dominant model) as 
well as with BD (OR = 2.210, P combined = 1.91 × 10−3 in a allelic model) 
after the multiple test correction in both replicated and combined analyses, 
which showed also a significant association between intestinal BD and BD 
without intestinal involvement before the multiple test correction (Table 2 and 
4). We identified ELMO1 (rs10259514) as new susceptible locus is associated 
with BD, which showed a stronger association with intestinal BD 
(rs10259514, OR = 0.706, P = 4.8 × 10−3 in a codominant model) than BD 
without intestinal involvement (rs10259514, OR = 0.724, P = 1.8 × 10−2 in 
codominant model) when compared to healthy controls. This different genetic 
risk reflects a specific biological significance of the presence of intestinal 
involvement (Table 2 and 3). Among previously implicated loci in GWAS 
studies,2-6, 26 CCR1-CCR3 (rs5742906), IL23R-IL12RB2 (rs12119179, 
rs1495965), HLA-F-AS1–HLA-A (rs4713242), and KLRC4-KLRK1
(rs2255336) and STAT4 (rs7574070) except PSORS1C1 (rs4959053) did not 
show a significant association with any subtypes of BD in our study, whereas 
ERAP1 (rs2927615) showed a significant association (OR = 2.744, P = 1.6 × 
10−2 in an allelic model) between intestinal BD and BD without intestinal 
involvement before the multiple test correction, reflecting that ERAP1
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increases intestinal involvement in BD. In addition, rs1518111 (OR = 0.717, P
= 7.5 × 10−3, in a codominant model), rs1554286 (OR = 0.789, P = 7.3 × 10−3
in a codominant model), and rs1800871 (OR = 0.730, P = 8.9 × 10−3 in a 
codominant model) in IL10 loci also showed significant association between 
intestinal BD or BD and healthy control, but no significant association with 
BD without intestinal involvement. rs7574070 in STAT4 (OR = 1.355, P = 4.2 
× 10−2 in a dominant model) also showed only significant association between 
BD and healthy control. These results indicate that our data set had an enough 
power (> 80%) to detect an association for these SNPs, although there is the 
present study’s limitation in sample size. Besides, intestinal BD showed 
modest evidence of association with CD180, DCAF12, PLCB1, and TGFBR3
as well as noncoding region LOC284395.
Table 2. Association results from comparison between patients with intestinal 
Behcet’s disease and Behcet’s disease without intestinal involvement
SNP MA Locus Nearby genes¶ GWAS P
Model
Replicated
aP value
Model
Combined
aP value
Model
OR
(95% CI) †
Combined
P†
Model
MAF
BD without 
intestinal 
involvement
Intestinal 
BD
rs3914501 G Chr. 3:
174564668
NAALADL2 1.1 × 10−1
Allelic
1.1 × 10−1
Allelic
1.1 × 10−1
Allelic
1.303
(0.88–1.928)
1.1 × 10−1
Allelic
0.487 0.537
rs16848171 C Chr. 3:
175181067
NAALADL2 5.0 × 10−3
Recessive
5.0 × 10−3
Recessive
5.0 × 10−3
Recessive
3.208
(1.367–7.529)
5.0 × 10−3
Recessive
0.217 0.248
rs32019 C Chr. 5:
66702373
CD180 9.9 × 10−3
Recessive
9.9 × 10−3
Recessive
9.9 × 10−3
Recessive
1.723
(1.137–2.61)
9.9 × 10−3
Recessive
0.483 0.548
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SNP MA Locus Nearby genes¶ GWAS P
Model
Replicated
aP value
Model
Combined
aP value
Model
OR
(95% CI) †
Combined
P†
Model
MAF
BD without 
intestinal 
involvement
Intestinal 
BD
rs6086653 A Chr.20:
8838343
PLCB1 1.5 × 10−2
Recessive
1.5 × 10−2
Recessive
1.5 × 10−2
Recessive
2.141
(1.144–4.007)
1.5 × 10−2
Recessive
0.266 0.293
rs284148 T Chr.1:
92277843
TGFBR3 1.6 × 10−2
Dominant
1.6 × 10−2
Dominant
1.6 × 10−2
Dominant
0.638
(0.442–0.921)
1.6 × 10−2
Dominant
0.446 0.381
rs12525170* A Chr. 22:
31099761
PSORS1C1 5.8 × 10−3
Dominant
5.8 × 10−3
Dominant
5.8 × 10−3
Dominant
0.595
(0.410–0.862)
5.8 × 10−3
Dominant
0.212 0.151
rs121917820 T Chr. 6:
31084794
PSORS1C1 No 
variation
No 
variation
No 
variation
No 
variation
rs7742033 G Chr. 6:
31085226
PSORS1C1
8.8 × 10−1
Codominan
t
8.8 × 10−1
Codominan
t
8.8 × 10−1
Codominan
t
0.801
(0.050–12.879)
8.8 × 10−1
Codominan
t
0.002 0.002
rs4959053* A Chr. 6:
31099577
PSORS1C1 1.1 × 10−2
Dominant
1.1 × 10−2
Dominant
1.1 × 10−2
Dominant
0.619
(0.425–0.9)
1.1 × 10−2
Dominant
0.204 0.148
rs5742906* T Chr. 3:
46306765
CCR1-CCR3 No 
variation
No 
variation
No 
variation
No 
variation
rs10259514 G Chr. 3:
36829705
ELMO1 5.5 × 10−1
Recessive
5.5 × 10−1
Recessive
5.5 × 10−1
Recessive
1.256
(0.596–2.645)
5.5 × 10−1
Recessive
0.256 0.250
rs17482078* T Chr. 5:
96118866
ERAP1
1.9 × 10−1
Codominan
t
1.9 × 10−1
Codominan
t
1.9 × 10−1
Codominan
t
1.529
(0.807–2.897)
1.9 × 10−1
Codominan
t
0.032 0.048
rs2927615* A Chr. 5:
96198202
ERAP1 1.6 × 10−2
Allelic
1.6 × 10−2
Allelic
1.6 × 10−2
Allelic
2.744
(1.172–6.427)
1.6 × 10−2
Allelic
0.016 0.041
rs4713242*
A
Chr. 6:
29718220
HLA-F-AS1–
HLA-A
4.0 × 10−1
Recessive
4.0 × 10−1
Recessive
4.0 × 10−1
Recessive
1.227
(0.763–1.971)
4.0 × 10−1
Recessive
0.398 0.399
rs1554286* G Chr. 1:
206944233
IL10 4.2 × 10−1
Recessive
4.2 × 10−1
Recessive
4.2 × 10−1
Recessive
0.758
(0.381–1.505)
4.2 × 10−1
Recessive
0.272 0.252
rs1800871* C Chr. 1:
206946634
IL10 4.1 × 10−1
Dominant
4.1 × 10−1
Dominant
4.1 × 10−1
Dominant
0.865
(0.611–1.223)
4.1 × 10−1
Dominant
0.266 0.245
rs1518111* C Chr. 1:
206944645
IL10 4.1 × 10−1
Allelic
4.1 × 10−1
Allelic
4.1 × 10−1
Allelic
0.889
(0.669–1.18)
4.1 × 10−1
Allelic
0.269 0.247
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SNP MA Locus Nearby genes¶ GWAS P
Model
Replicated
aP value
Model
Combined
aP value
Model
OR
(95% CI) †
Combined
P†
Model
MAF
BD without 
intestinal 
involvement
Intestinal 
BD
rs12119179* C Chr. 1:
67747415
IL23R-IL12RB2
4.1 × 10−1
Codominan
t
4.1 × 10−1
Codominan
t
4.1 × 10−1
Codominan
t
0.902
(0.705–1.154)
4.1 × 10−1
Codominan
t
0.515 0.489
rs1495965* C Chr. 1:
67753508
IL23R-IL12RB2 5.9 × 10−1
Dominant
5.9 × 10−1
Dominant
5.9 × 10−1
Dominant
0.894
(0.593–1.347)
5.9 × 10−1
Dominant
0.521 0.514
rs2255336*
T
Chr. 12:
10532326
KLRC4-KLRK1 6.6 × 10−1
Recessive
6.6 × 10−1
Recessive
6.6 × 10−1
Recessive
0.801
(0.296–2.169)
6.6 × 10−1
Recessive
0.188 0.185
rs7574070* A Chr. 2:
192010488
STAT4
8.9 × 10−1
Codominan
t
8.9 × 10−1
Codominan
t
8.9 × 10−1
Codominan
t
1.025
(0.685–1.535)
8.9 × 10−1
Codominan
t
0.491 0.487
rs6838327 A Chr. 4:
44626846
YIPF7 3.4 × 10−4
Allelic
3.4 × 10−4
Allelic
3.4 × 10−4
Allelic
1.567
(1.225–2.005)
3.4 × 10−4
Allelic
0.408 0.519
rs7245731 A Chr. 19:
29975118
LOC284395 1.4 × 10−2
Recessive
1.4 × 10−2
Recessive
1.4 × 10−2
Recessive
0.113
(0.014–0.925)
1.4 × 10−2
Recessive
0.139 0.127
The replication study were performed 391 healthy controls and 264 intestinal 
BD samples including 100 systemic BD samples used in GWAS.*Discovered 
loci described previously. Allele frequencies are presented for the discovery 
sample. ¶Nearby genes are defined as the closest genes to the SNP within 
signal boundary or the closest genes within a 200-kb window. †Combined P-
value, combined OR (CI), or combined MAF obtained from Cochran–
Mantel–Haenszel test statistic (1 df). SNP, single nucleotide polymorphism; 
Chr., chromosome; MA, minor allele; GWAS, genome-wide association 
study; OR, odds ratio; 95% CI, 95% confidence interval; MAF, minor allele 
frequency.
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Table 3. Association results from comparison between healthy controls and 
patients with intestinal Behcet’s disease
SNP MA Locus
Nearby 
genes¶
GWAS P
Model
Replicated
aP value
Model
Combined
aP value
Model
OR
(95% CI) †
Combined
P†
Model
MAF
Healthy 
control
Intestinal 
BD
rs3914501 G Chr. 3:
174564668
NAALADL2 5.7× 10−5
recessive
1.6 × 10−2
Recessive
3.8 × 10−4
Recessive
1.914
(1.338–2.738)
3.5 × 10−4
Recessive
0.459 0.537
rs16848171 C Chr. 3:
175181067
NAALADL2 1.4× 10−5
Recessive
9.2× 10−2
Recessive
7.0× 10−3
Recessive
2.462
(1.279–4.739)
5.6 × 10−3
Recessive
0.219 0.248
rs32019 C Chr. 5:
66702373
CD180 1.8 × 10−3
Codominant
4.4 × 10−2
Codominant
4.0 × 10−3
Codominant
1.265
(1.023–1.563)
3.8 × 10−3
Codominant
0.487 0.548
rs6086653 A Chr.20:
8838343
PLCB1 3.5 × 10−5
Dominant
6.2 × 10−1
Dominant
4.3 × 10−2
Dominant
0.729
(0.537–0.99)
4.3 × 10−2
Dominant
0.312 0.293
rs284148 T Chr.1:
92277843
TGFBR3 4.8 × 10−5
Dominant
3.5 × 10−1
Dominant
1.2 × 10−2
Dominant
0.667
(0.486–0.916)
1.2 × 10−2
Dominant
0.425 0.381
rs12525170* A Chr. 22:
31099761
PSORS1C1 4.7 × 10−2
Allelic
4.7 × 10−2
Allelic
8.5 × 10−2
Allelic
1.318
(0.962–1.805)
8.5 × 10−2
Allelic
0.119 0.151
rs121917820 T Chr. 6:
31084794
PSORS1C1 No 
variation
No variation No variation
No 
variation
rs7742033 G Chr. 6:
31085226
PSORS1C1 6.4 × 10−1
Codominant
6.4 × 10−1
Codominant
8.4 × 10−1
Codominant
1.323
(0.082–21.241)
8.4 × 10−1
Codominant
0.001 0.002
rs4959053* A Chr. 6:
31099577
PSORS1C1 7.6 × 10−2
Allelic
7.7 × 10−1
Allelic
1.2 × 10−1
Allelic
1.285
(0.937–1.760)
1.2 × 10−1
Allelic
0.119 0.148
rs5742906* T Chr. 3:
46306765
CCR1-CCR3 No 
variation
No variation No variation
No 
variation
rs10259514 G Chr. 3:
36829705
ELMO1 7.7 × 10−6
Allelic
1.4 × 10−1
Allelic
4.8 × 10−3
Allelic
0.706
(0.554–0.899)
4.8 × 10−3
Allelic
0.320 0.249
rs17482078* T Chr. 5:
96118866
ERAP1 1.6 × 10−1
Recessive
9.9 × 10−1
Recessive
9.9 × 10−1
Recessive
∞
(0–∞)
2.5 × 10−1
Recessive
0.046 0.048
rs2927615* A Chr. 5:
96198202
ERAP1 1.6 × 10−1
Recessive
9.9 × 10−1
Recessive
9.9 × 10−1
Recessive
∞
(0–∞)
2.5 × 10−1
Recessive
0.032 0.041
rs4713242* A Chr. 6:
29718220
HLA-F-AS1–
HLA-A
9.2 × 10−1
Recessive
9.2 × 10−1
Recessive
5.3 × 10−1
Recessive
1.141
(0.757–1.720)
5.3 × 10−1
Recessive
0.391 0.399
rs1554286* G Chr. 1:
206944233
IL10 4.0 × 10−3
Codominant
2.1 × 10−2
Codominant
0.717
(0.562–0.915)
7.3 × 10−3
Codominant
0.318 0.252
rs1800871* C Chr. 1:
206946634
IL10
!
5.8 × 10−3
Codominant
2.1 × 10−2
Codominant
0.730
(0.563–0.948)
8.9 × 10−3
Codominant
0.309 0.245
rs1518111* C Chr. 1:
206944645
IL10 1.4 × 10−5
Codominant
5.6 × 10−3
Codominant
7.8 × 10−3
Codominant
0.717
(0.562-0.916)
7.5 × 10−3
Codominant
0.313 0.247
34
SNP MA Locus
Nearby 
genes¶
GWAS P
Model
Replicated
aP value
Model
Combined
aP value
Model
OR
(95% CI) †
Combined
P†
Model
MAF
Healthy 
control
Intestinal 
BD
rs12119179* C Chr. 1:
67747415
IL23R-
IL12RB2
8.8 × 10−3
Recessive
9.5 × 10−1
Recessive
3.3 × 10−1
Recessive
1.196
(0.832–1.722)
3.3 × 10−1
Recessive
0.478 0.489
rs1495965* C Chr. 1:
67753508
IL23R-
IL12RB2
4.0 × 10−1
Recessive
1.7 × 10−1
Recessive
1.283
(0.901–1.828)
1.7 × 10−1
Recessive
0.494 0.514
rs2255336*
T
Chr. 12:
10532326
KLRC4-
KLRK1
2.7 × 10−1
Codominant
1.8 × 10−1
Codominant
0.828
(0.630–1.088)
1.8 × 10−1
Codominant
0.214 0.185
rs7574070* A Chr. 2:
192010488
STAT4 8.0 × 10−2
Dominant
7.3 × 10−2
Dominant
1.370
(0.971–1.934)
7.3 × 10−2
Dominant
0.459 0.491
rs6838327 A Chr. 4:
44626846
YIPF7 1.2 × 10−1
Recessive
6.4 × 10−3
Recessive
1.654
(1.152–2.376)
6.2 × 10−3
Recessive
0.468 0.519
rs7245731 A Chr. 19:
29975118
LOC284395 9.9 × 10-1
Recessive
9.9 × 10-1
Recessive
-
2.5 × 10-1
Recessive
0.133 0.127
The replication study were performed 391 healthy controls and 295 intestinal 
BD samples including 99 intestinal BD samples used in GWAS.*Discovered 
loci described previously. Allele frequencies are presented for the discovery 
sample. ¶Nearby genes are defined as the closest genes to the SNP within 
signal boundary or the closest genes within a 200-kb window. †Combined P-
value, combined OR (CI), or combined MAF obtained from Cochran–
Mantel–Haenszel test statistic (1 df). SNP, single nucleotide polymorphism; 
Chr., chromosome; MA, minor allele; GWAS, genome-wide association 
study; OR, odds ratio; 95% CI, 95% confidence interval. ap_value: Logistic 
regression analysis
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Table 4. Association results from comparison between healthy controls and 
Behcet’s disease patients without intestinal involvement
SNP MA Locus
Nearby 
genes¶
GWAS P
Model
Replicated
aP value
Model
Combined
aP value
Model
OR
(95% CI)
†
Combined 
P†
Model
MAF
Healthy 
control
BD without 
intestinal 
involvement
rs3914501 G Chr. 3:
174564668
NAALADL2
8.7 × 10−2
Codomina
nt
7.8 × 10−2
Codominant
3.4 × 10−1
Codominant
1.122
(0.886–
1.422)
3.4 × 10−1
Codominant
0.459 0.487
rs16848171 C Chr. 3:
175181067
NAALADL2 6.2 × 10−1
Recessive
4.1 × 10−1
Recessive
5.7 × 10−1
Recessive
0.768
(0.308–
1.911)
5.7 × 10−1
Recessive
0.219 0.217
rs32019 C Chr. 5:
66702373
CD180 2.4 × 10−1
Recessive
3.3 × 10−1
Recessive
3.9 × 10−2
Recessive
0.658
(0.442–
0.98)
3.9 × 10−2
Recessive
0.487 0.483
rs6086653 A Chr.20:
8838343
PLCB1
2.8 × 10−1
Codomina
nt
1.9 × 10−1
Codominant
7.9 × 10−2
Codominant
0.792
(0.61–
1.028)
7.9 × 10−2
Codominant
0.312 0.266
rs284148 T Chr.1:
92277843
TGFBR3 4.4 × 10−1
Recessive
8.4 × 10−1
Recessive
3.0 × 10−1
Recessive
1.25
(0.823–
1.897)
3.0 × 10−1
Recessive
0.425 0.446
rs12525170* A Chr. 6:
31207740
PSORS1C1 1.1 × 10−3
Dominant
1.1 × 10−5
Dominant
2.210
(1.546–
3.157)
1.1 × 10−5
Dominant
0.119 0.212
rs121917820 T Chr. 6:
31084794
PSORS1C1
No variation No variation
No 
variation
rs7742033 G Chr. 6:
31085226
PSORS1C1 2.0 × 10−1
Codominant
7.2 × 10−1
Codominant
1.648
(0.103–
26.477)
7.2 × 10−1
Codominant
0.001 0.002
rs4959053* A Chr. 6:
31099577
PSORS1C1 2.2 × 10−5
Allelic
7.7 × 10−2
Allelic
5.6 × 10−5
Allelic
1.892
(1.383–
2.589)
5.6 × 10−5
Allelic
0.119 0.203
rs5742906* T Chr. 3:
46306765
CCR1-CCR3 No 
variation
No variation No variation
No 
variation
rs10259514 G Chr. 3:
36829705
ELMO1
6.8 × 10−2
Codomina
nt
1.7 × 10−2
Codominant
1.7 × 10−2
Codominant
0.724
(0.556–
0.944)
1.7 × 10−2
Codominant
0.320 0.256
rs17482078* T Chr. 5:
96118866
ERAP1 5.3 × 10−2
Codominant
2.1 × 10−1
Codominant
0.669
(0.358–
1.251)
2.1 × 10−1
Codominant
0.046 0.032
rs2927615* A Chr. 5:
96198202
ERAP1 5.0 × 10−2
Codominant
7.5 × 10−2
Codominant
0.468
(0.199–
1.100)
7.5 × 10−2
Codominant
0.032 0.016
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SNP MA Locus
Nearby 
genes¶
GWAS P
Model
Replicated
aP value
Model
Combined
aP value
Model
OR
(95% CI)
†
Combined 
P†
Model
MAF
Healthy 
control
BD without 
intestinal 
involvement
rs4713242*
A
Chr. 6:
29718220
HLA-F-
AS1–HLA-
A
6.4 × 10−1
Dominant
5.7 × 10−1
Dominant
1.104
(0.788–
1.548)
5.7 × 10−1
Dominant
0.391 0.397
rs1554286* G Chr. 1:
206944233
IL10
1.4 × 10−1
Codomina
nt
5.7 × 10−1
Codominant
8.5 × 10−2
Codominant
0.801
(0.621–
1.032)
8.5 × 10−2
Codominant
0.318 0.272
rs1800871* C Chr. 1:
206946634
IL10 4.6 × 10−3
Dominant
1.0 × 10−1
Dominant
0.806
(0.622–
1.044)
1.0 × 10−1
Dominant
0.309 0.266
rs1518111* C Chr. 1:
206944645
IL10 3.2 × 10−3
Dominant
1.0 × 10−1
Dominant
0.758
(0.545–
1.055)
1.0 × 10−1
Dominant
0.313 0.278
rs12119179* C Chr. 1:
67747415
IL23R-
IL12RB2
1.1 × 10−1
Recessive
2.2 × 10−1
Recessive
1.0 × 10−1
Recessive
1.369
(0.938–
2.000)
1.0 × 10−1
Recessive
0.478 0.515
rs1495965* C Chr. 1:
67753508
IL23R-
IL12RB2
8.2 × 10−1
Recessive
2.0 × 10−1
Recessive
1.276
(0.877–
1.855)
2.0 × 10−1
Recessive
0.494 0.523
rs2255336*
T
Chr. 12:
10532326
KLRC4-
KLRK1
3.3 × 10−1
Allelic
1.2 × 10−1
Allelic
2.7 × 10−1
Allelic
0.85
(0.637–
1.134)
2.7 × 10−1
Allelic
0.214 0.188
rs7574070* A Chr. 2:
192010488
STAT4 4.0 × 10−1
Dominant
8.7 × 10−2
Dominant
1.2 × 10−1
Dominant
1.337
(0.924–
1.933)
1.2 × 10−1
Dominant
0.459 0.487
rs6838327 A Chr. 4:
44626846
YIPF7 3.9 × 10−4
Dominant
3.6 × 10−1
Dominant
1.0 × 10−2
Dominant
0.630
(0.442–
0.897)
1.0 × 10−2
Dominant
0.468 0.408
rs7245731 A Chr. 19:
29975118
LOC284395 1.9 × 10-9
Recessive
9.9 × 10-1
Recessive
6.3 × 10-4
Recessive
-
6.3 × 10-4
Recessive
0.133 0.139
The replication study were performed 391 healthy controls and 264 intestinal 
BD samples including 100 systemic BD samples used in GWAS.*Discovered 
loci described previously. Allele frequencies are presented for the discovery 
sample. ¶Nearby genes are defined as the closest genes to the SNP within 
signal boundary or the closest genes within a 200-kb window. †Combined P-
value, combined OR (CI), or combined MAF obtained from Cochran–
Mantel–Haenszel test statistic (1 df). SNP, single nucleotide polymorphism; 
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Chr., chromosome; MA, minor allele; GWAS, genome-wide association 
study; OR, odds ratio; 95% CI, 95% confidence interval; MAF, minor allele 
frequency.
3. Haplotype analysis
For multifactorial diseases, single variant on a particular gene may have no 
strong effect, but the combination of multiple variants with small effects 
explains the overall susceptibility to the disease.27 To better evaluate genetic 
associations at haplotype level, we selected 11 gene loci from GWAS data and 
conducted a haplotype analysis with the additional proxy SNPs in the 
DCAF12, ERAP1, IL10, IL23R-IL12RB2, SCHIP1, NAALADL2, PLCB1, 
PSORS1C1, and TGFBR3 showing multiple signals from GWAS. While 
IL23R-IL12RB2 did not show an association with any type of BD, DCAF12, 
IL10, NAALADL2, PLCB1, SCHIP1, and TGFBR3 showed associations with 
intestinal BD development in haplotype analysis, which was consistent with 
our replication results: DCAF12 (C-A, OR = 0.619, P = 2.4 × 10−3 between 
intestinal BD vs. healthy control), IL10 (G-C-C, OR = 0.712, P = 7.3 × 10−3
between intestinal BD vs. healthy control), NAALADL2 (T-G, OR = 0.473, P
= 1.7 × 10−2 between intestinal BD vs. healthy controls; T-G, OR = 0.347, P = 
7.3 × 10−3 between intestinal BD vs. BD without intestinal involvement ), 
PLCB1 (C-C-T-T-G, OR = 1.465, P = 1.5 × 10−2 between intestinal BD vs. 
healthy control), SCHIP1 (G-C, OR = 1.613, P = 3.2 × 10−3 between intestinal 
38
BD vs. healthy control), and TGFBR3 (C-C-G, OR = 1.481, P = 2.2 × 10−2
between intestinal BD vs. healthy control), suggesting these genes to be 
potential causal variants contributing to intestinal BD development (Table 5). 
Among these loci, the significant associations of NAALADL2 and PSORS1C1
were remained in comparisons between intestinal BD and BD without 
intestinal involvement. On the other hands, only PSORS1C1 showed a 
significant association with BD without intestinal involvement (G-G-G, OR = 
0.511, P = 1.5 × 10−5 between BD without intestinal involvement vs. healthy 
control), which might have a negative correlation for intestinal involvement.
Table 5. Halplotype analysis of susceptible genes for intestinal Behcet disease
and Behcet disease without intestinal involvement
Closest genes Haplotype Combined P† Model OR (95% CI) †
Intestinal BD (n = 295) vs. healthy control (n = 391)
DCAF12 C-A 2.4 × 10−3 Dominant 0.619 (0.454–0.843)
T-G 5.4 × 10−3 Recessive 1.55 (1.138–2.111)
IL10 A-T-T 1.2 × 10−2 Codominant 1.374 (1.073–1.76)
G-C-C 7.3 × 10−3 Codominant 0.712 (0.555–0.913)
NAALADL2 C-G 5.5 × 10−2 Recessive 2.079 (0.985-4.388)
T-C 6.4 × 10−1 Dominant 1.137 (0.66-1.961)
T-G 1.7 × 10−2 Dominant 0.473 (0.255–0.876)
PLCB1 C-C-T-T-G 1.5 × 10−2 Recessive 1.465 (1.077–1.993)
G-T-C-C-A 9.1 × 10−2 Dominant 0.768 (0.565-1.044)
SCHIP1 C-T 7.3 × 10−3 Recessive 0.649 (0.473–0.890)
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Closest genes Haplotype Combined P† Model OR (95% CI) †
G-C 3.2 × 10−3 Dominant 1.613 (1.174–2.217)
TGFBR3 C-C-G 2.2 × 10−2 Recessive 1.481 (1.059–2.070)
C-T-A 1.4 × 10−1 Dominant 0.793 (0.582-1.080)
BD without intestinal involvement (n =264) vs. healthy controls (n = 391)
PSORS1C1 G-A-A 2.4× 10−5 Allelic 1.935 (1.424–2.628)
G-G-G 1.5 × 10−5 Allelic 0.511 (0.377–0.693)
A-A 3.7× 10−5 Allelic 1.917 (1.412–2.602)
G-G 2.1 × 10−5 Allelic 0.515 (0.380–0.699)
Intestinal BD (n = 295) vs. BD without intestinal involvement (n =264)
NAALADL2 C-G 1.7 × 10−2 Recessive 3.401 (1.245–9.296)
T-C 4.1 × 10−1 Dominant 0.791 (0.453-1.382)
T-G 7.3 × 10−3 Dominant 0.347 (0.16–0.751)
PSORS1C1 G-A-A 9.7 × 10−3 Dominant 0.617 (0.428–0.889)
G-G-G 9.4 × 10−3 Recessive 1.619 (1.125–2.329)
A-A 9.7 × 10−3 Dominant 0.617 (0.428–0.889)
G-G 9.6 × 10−3 Recessive 1.62 (1.125–2.333)
SNPs were excluded if they had a minor allele frequency (MAF) < 0.05 and 
SNPs distant > 100 kB. The risk allele is underlined. †Combined P-value, 
combined OR (CI), or combined MAF obtained from Cochran–Mantel–
Haenszel test statistic (1 df). OR, odds ratio; 95% CI, 95% confidence 
interval; MAF, minor allele frequency.
4. Clinical phenotypes and outcomes according to genotypes
We assessed whether the investigated SNPs could have influence clinical 
manifestations including intestinal complications and prognosis such as 
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cumulative probabilities of operation, hospitalization, corticosteroid use, and 
immunosuppressant use in intestinal BD patients. In intestinal BD, ERAP1
(rs17482078 and rs2927615) and HLA-F-AS1–HLA-A (rs4713242) were 
associated with bowel perforation. ELMO1 (rs10259514) and DCAF12
(rs10758242) were associated with intestinal fistula development, whereas 
TGFBR3 (rs1805110 and rs284148) was associated with intestinal stricture
(Table 6). In terms of clinical outcomes, NAALADL2 (rs3914501) and 
TGFBR3 (rs1805110 and rs17882828) risk alleles were associated with a 
higher cumulative probability of surgery, whereas PSORS1C1 (rs12525170)
and STAT4 (rs7574070) risk alleles were associated with a lower cumulative 
probability of surgery. NAALADL2 (rs3914501 and rs16848171) risk alleles
were associated with a higher cumulative probability of hospitalization.
NAALADL2 (rs3914501 and rs16848171) and IL23R-IL12RB2 (rs1495965)
risk alleles were associated with a higher cumulative probability of 
corticosteroid use, suggesting more poor prognosis (Figure 5).
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Table 6. Intestinal complications according to SNP genotypes in intestinal BD 
patients 
Phenotype Gene and 
rs number
Genotype
or allele
Patients 
with 
pheneotype 
(%)
Patients 
without 
pheneotype 
(%)
aOR 
(95% CI)
P
value
  
Perforation
ERAP1
rs17482078
dominant CC
CT/TT
20(76.9)
6 (23.1)
244(92.1)
21 (7.9)
3.49 
(1.26-9.62)
0.016
ERAP1
rs2927615
dominant GG
GA/AA
20 (76.9)
6 (23.1)
246 (93.5)
17 (6.5)
4.34
(1.54-12.24)
0.005
HLA-F-
AS1–HLA-A
rs4713242
allele A
G
14 (26.9)
38 (73.1)
218 (41.3)
310 (58.7)
0.52
(0.28-0.99)
0.047
Fistula ELMO1
rs10259514
allele G
A
19(39.58)
29(60.42)
123(23.65)
397(76.35)
2.12 
(1.15-3.90)
0.017
DCAF12
rs10758242
dominant GG
AG/AA
19(79.2)
5 (20.8)
142(55.7)
113 (44.3)
0.33
(0.12-0.91)
0.033
Stricture TGFBR3
rs1805110
dominant GG
GA/AA
4 (16.0)
21 (84.0)
101 (37.7)
167 (62.3)
3.17
(1.06-9.51)
0.039
TGFBR3
rs284148
allele T
C
26 (59.1)
18 (40.9)
192 (36.5)
334 (63.5)
2.51
(1.34-4.70)
0.004
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(A)
(B)
43
(C)
Figure 5. Cumulative probabilities of surgery (A), hospitalization (B), and 
corticosteroid use (C) according to SNP genotypes in intestinal BD patients. 
Blue line show risk allele.
We also evaluated whether the investigated SNPs could influence clinical 
manifestations in BD without intestinal involvement. PSORS1C1 (rs12525170
and rs4959053) and IL10 (rs1554286) were related with HLA-B51 positivity, 
while YIPF7 (rs6838327) was related with development of genital ulcers. 
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IL10 (rs1554286 and rs1957895) was associated with skin involvement and 
HLA-F-AS1–HLA-A (rs4713242) was associated with vascular involvement. 
PSORS1C1 (rs12525170 and rs4959053) was related with central nervous 
system involvement (Table 7).
Table 7. Clinical manifestations according to SNP genotypes in BD patients
without intestinal involvement
Phenotype Gene and 
rs number
Genotype
or allele
Patients 
with 
pheneotype 
(%)
Patients 
without 
pheneotype 
(%)
aOR 
(95% CI)
P 
value
HLA-B51
positivity
PSORS1C1
rs12525170
dominant GG
AG/AA
11 (13.6)
70 (86.4)
127 (90.1)
14 (9.9)
56.39
(24.22-131.32)
<0.001
PSORS1C1
rs4959053
dominant GG
AG/AA
11 (11.9)
68 (86.1)
128 (90.8)
13 (9.2)
59.53 
(25.26-140.30)
<0.001
IL10
rs1554286
dominant AA
GA/GG
37 (44.6)
46 (55.4)
81(57.0)
61 (43.0)
1.75
(1.00-3.05)
0.048
Genital 
ulcers
YIPF7
rs6838327
allele A
G
177 (42.6)
239 (57.5)
13 (56.0)
37 (74.0)
2.11 
(1.08-4.11)
0.029
Skin 
lesions
IL10
rs1554286
codominant AA
GA
GG
120 (54.8)
84 (38.4)
15 (6.9)
6 (33.3)
9 (50.0)
3 (16.7)
0.47
(0.23-0.99)
0.049
IL10
rs1957895
dominant TT
GT/GG 
79(36.1)
140 (63.9)
13(72.2)
5 (27.8)
4.82
(1.63-14.23)
0.004
CNS
lesions
PSORS1C1
rs12525170
recessive GG/AG
AA
3 (60.0)
2 (40.0)
221 (96.5)
8 (3.5)
23.23
(3.05-176.79)
0.002
PSORS1C1
rs4959053
recessive GG/AG
AA
3 (60.0)
2 (40.0)
218 (96.5)
8 (3.5)
22.91 
(3.02-174.09)
0.002
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5. Gene function analysis
To establish biological relevance those SNPs to disease, we explored the 
possible functional consequences of the selected 47 SNPs, focusing on 
existing regulatory SNP and QTL databases containing various cell lines and 
tissues. rs17482078 (p.Arg725Gln) in ERAP1 and rs9866564 (p.Pro622Arg) 
in NAALADL2 causing missense mutations were predicted to possibly damage 
in silico analysis. For further investigation, we performed 
immunohistochemical analysis with colon tissues from intestinal BD patients 
and normal tissues from cancer patients after intestinal surgery for 
NAALADL2 and YIPF7 which were significantly associated with intestinal
BD development by more than one method. We detected expression of 
NAALADL2 and YIPF7 in the intestinal epithelium, in which protein 
expressions of NAALADL2 and YIPF7 were associated with increased 
proportions of abnormal crypts and significantly decreased in the colon tissues 
of patients with IBD and BD when compared to control tissues (Figure 6).
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Figure 6. Gene expression in human and mouse colon tissues. (A, B) 
Immunohistochemistry of human colon tissues colon tissue was performed 
against NAALADL2 (A) and YIPF7 (B) and the expression of according to 
diseases and SNP genotypes (NAALADL2: rs3914501; YIPF7: rs6838327)
was evaluated. Right panels show stain intensity. Sections were 
counterstained with hematoxylin. (C–E) mRNA levels in colon tissues of 
human and mouse. Total RNAs were isolated and converted into cDNA from 
mouse colon tissues. Transcript levels of NAALADL2 (C, left), YIPF7 (C, 
right), IL17 (D, left), and IL10 (D, right) from human colon tissues and 
Naaladl2 (E, left), Yipf7 (E, right) from mouse were quantified by real-time 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) and 
normalized to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or β-
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actin. * P < 0.05 vs. CTL, ** P < 0.005 vs. CTL or Sham. BD, Behcet 
diseases; CD, Crohn’s disease; CTL, control; UC, ulcerative colitis.
Furthermore, the candidate SNPs were examined for potential regulatory 
functions using RegulomeDB annotating with reference to experimentally 
supported regulatory elements. Two of the 3 SNPs indicating a relatively high 
degree of evidence for potential regulatory function were located in IL10
(rs1554286, score =1f; rs1518111, score = 3a) and in TGFBR3 (rs17882828, 
score= 2b), which are affecting the binding of CREB Binding Protein 
(CREBBP) and CCAAT/Enhancer Binding Protein beta (CEBPB) involved in 
colon inflammation28 and IL17 signaling pathway.29 To explore additional 
regulatory mechanisms for the linked SNP set on haplotype blocks using LD 
information, we use the HaploReg tool. The search of HaploReg indicated 
that rs3914501 and rs16848171 in NAALADL2, rs12525170 in PSORS1C1, 
rs10259514 in ELMO1, rs10758242 in DCAF12, rs1805110 and rs284148 in 
TGFBR3 were located in predicted regulatory motifs (Cdx, TAL1; Alx4, GR, 
Smad4; TBX5; Hltf, YY1; AIRE, AP-3, Alx4; Osr; PLAG1), suggesting a 
potential regulatory role. In the high LD block with rs6086653 in PLCB1, 
there are SNPs that may affect regulatory motifs (rs6086632 and rs6039302: 
Foxp1; rs12624809: E2F, Irf; rs6086633: NERF1a, Pou2f2, TEF; rs6086653: 
Esr2, Spz1). Furthermore, rs17482078 in ERAP1 and rs1805110 and rs284148 
in TGFBR3 located in an evolutionary conserved region predicted to be under 
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functional constraint based on SiPhy analysis. The eQTL analyses revealed a 
significant associated locus (rs2927615) with its own expressions (ERAP1) 
after Bonferroni corrections. In addition, risk alleles of rs2927615 including 
rs10441723 (DCAF12), rs1805110 (ELMO1), rs1554286 (IL10) showed 
down-regulation of IL10 expression in lymphocytes and fibroblasts. Moreover, 
risk alleles of rs10441723 and rs1805110 in ELMO1, rs1554286 in IL10, 
rs1805110 in TGFBR3, rs7245731 in LOC284395, and rs4959053 in 
PSORS1C1, showed the gene expressions of pro-inflammatory cytokines, 
CCR1, CCR3, and IL12RB2 as well as KLRC4, PSORS1C1, and STAT4
(Figure 7). These results suggest that many of the risk variants have multiple 
regulatory and functional features at its locus.
(A) rs2927615 in ERAP1
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(B) rs10441723 in DCAF12
(C) rs10758242 in DCAF12
(D) rs1805110 in ELMO1
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(E) rs4959053 in PSORS1C1
(F) rs1554286 in IL10
51
(G) rs1805110 in TGFBR3
(H) rs6838327 in YIPF7
(I) rs7245731 in LOC284395
Figure 7. Expression quantitative trait loci (eQTL) analysis. (A) rs2927615 in
ERAP1. (B) rs10441723 in DCAF12. (C) rs10758242 in DCAF12.  (D)
rs1805110 in ELMO1. (E) rs4959053 in PSORS1C1. (F) rs1554286 in IL10.  
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(G) rs1805110 in TGFBR3. (H) rs6838327 in YIPF7.  (I) rs7245731 in
LOC284395. Results were plotted from probes located of each SNP of
HapMap3 (CEU, CHB, GIH, JPT, LWK, MEX, MKK, YRI; Stranger et al., 
2012) and Geneva Gencord (Dimas et al., 2009) studies. A: adipose tissue; F, 
fibroblast; T, T-cell; S, skin; F, fat; L, lymphoblastoid cell line. Asterisks and 
red boxes show a significant eQTLs among candidate SNPs for BD after 
10,000 permutations and risk alleles, resepctively.
To identify the potential biological pathways with the genes responsible for 
disease susceptibility from GWAS and the replicated SNPs, we used IPA 
based on published data. We examined overlap of our significant regions 
against published GWAS results (GWAS catalog). One functional network of 
3 identified networks from the lists (14 genes) from BD GWAS catalog 
included 9 focus molecules, which has a potential function in T helper cell 
differentiation (P = 2.83 ´ 10-8), IL12 signaling and production in macrophage 
(P = 3.79 ´ 10-7), IL10 signaling (P = 4.88 ´ 10-4), and dendritic cell 
maturation (P = 3.31 ´ 10-3). The top functional network of 25 networks from 
lists (536 genes) of IBD GWAS catalog included 26 focus molecules and has 
a potential function in T helper cell differentiation (P = 2.97 ´ 10-29), dendritic 
cell maturation (P = 8.27 ´ 10-24), and crosstalk between dendritic cells and 
natural killer cells (P = 5.7 ´ 10-22).
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Notably, the pathways analyses showed that the intestinal BD genes (13 
genes) have one functional network included 11 focus molecules and 
overlapped with 8 networks (Network 5, 9, 10, 13, 15, 16, 22, 23) of IBD 
GWAS genes, suggesting that the phenotype of intestinal involvement shares 
common risk factors with IBD (Figure 8A and Figure 9B). Although intestinal 
BD genes have only one network (Network 1) directly connected with genes 
from BD GWAS, these interactions may also connect indirectly intestinal BD 
pathway with IBD pathway (networks 2, 11: Figure 8B). In addition, the 
functional network shares common potential function in PI3K signaling in B 
lymphocytes (PLCB1, CD180) and CXCR4 (PLCB1, ELMO1) signaling with 
2 focus molecules (CD180, ELMO1) from the lists (5 genes) from BD 
without intestinal involvement (Figure 9A), suggesting that intestinal BD 
genes shows BD phenotypes through interaction with genes with BD without 
intestinal involvement as well as intestinal involvement. In addition, 
comparisons between BD genes and IBD genes from GWAS catalog, 2 
networks of BD (Network 1, Network 3) were overlapped with IBD networks, 
in which Network 1 is linked to Network 2 and Network 11 of IBD networks
(Figure 9C). These results support the potential for crosstalk between 
intestinal BD and BD without intestinal involvement.
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Figure 8. Pathway analyses of genes susceptible to intestinal BD, BD without 
intestinal involvement, and IBD. (A) Networks of overlapping between 
intestinal BD and IBD. (B) Connection of intestinal involvement phenotype of 
BD through networks between BD without intestinal involvement and IBD.
Genes implicated by the SNPs shown to be associated with intestinal BD and 
BD without intestinal involvement at genome-wide significance are 
highlighted in purple and red, respectively. A core analysis was run on these 
genes with default settings.
(A)
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Figure 9. Network Diagram of BD susceptible genes. (A) Comparisons of 
pathways of intestinal BD, BD without intestinal involvement, and IBD. (B) 
Networks of overlapping among intestinal BD, BD without intestinal 
involvement, and IBD. (C) Networks of overlapping between BD without 
intestinal involvement and IBD. A core analysis was run on these genes with 
default settings. Genes implicated by the SNPs shown to be associated with 
BD without intestinal involvement at genome-wide significance are 
highlighted in red.
IV. DISCUSSION
This is the first study to elucidate the specific genetic polymorphisms 
contributing to the susceptibility to intestinal involvement in BD. 
Comparisons within intestinal BD and healthy control or BD without 
intestinal involvement showed intestinal BD-specific associations of locus 
nearby NAALADL2 (N-acetyl-L-aspartyl-L-glutamate peptidase I) gene and 
YIPF7 (Yip1 domain family member 7) gene. In addition, a computational 
protein prediction suggested that the missense mutations of NAALADL2 and 
YIPF7 are possibly damaging to their corresponding proteins. Moreover, 
NAALADL2-associated rs3914501 risk allele was related with higher 
cumulative probabilities of surgery, hospitalization, and corticosteroid use. 
Our results suggest that NAALADL2 gene may be associated with poor 
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prognosis as well as development of intestinal BD. Previously, the 
rs17531088, NAALADL2-associated risk allele, was reported to be linked to 
development of Kawasaki disease and Cornelia de Lange syndrome, a rare 
developmental malformation syndrome.30, 31 Of note, SNP in NAALADL2
(rs62285902) was also observed in CD genome-wide imputation analysis 
from Japanese population as candidate gene (OR = 0.63 (0.62–0.65)), 
although the SNP was not validated in replication study.32 Considering that 
Kawasaki disease affects the blood vessels and BD is also a form of vasculitis, 
it is interesting that NAALADL2 showed the novel association with intestinal 
BD in our replication analysis as well as subsequent haplotype analysis 
replication study. Dysfunction of YIP1 family member may dysregulate 
intestinal homeostasis leading to pathogenic states.33 In addition, mice in 
which Yipf6 functioning in membrane trafficking and vesicle biogenesis was 
null mutated were extremely sensitive to colitis induced by dextran sodium 
sulfate and regarded as a susceptibility locus of IBD in humans in one study. 
We identified more frequent variations of YIPF7, known as another YIP1 
family member including Yipf6, in intestinal BD compared to BD without 
intestinal involvement. YIPF7 was not included in the pathway analysis
results, probably because the exact function of this protein is still unknown.
Our eQTL analysis demonstrated that rs3914501 in NAALADL2 increase the 
expression of IL13 and IL22 and rs6838327 in YIPF7 increase the expression 
of IL12RB2 in lymphoblastoid cells. 
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IL-23 drives expression of IL-17 in CD4+ T cells coupled with the distinct 
functional roles of IL-12,34 in which IL-22 and CEBPB was induced and act 
in concert to mediate the pro-inflammatory effects.35 CEBPs are known to be 
critical regulators of IL6 expression.35 Our data show increased IL17 
expression in colon tissues of BD patients along with decreased IL10 
expression. Patients with CD exhibited increased lamina propria IL12 
production.36
Furthermore, the IHC showed that the expression of NAALADL2 and 
YIPF7 not only was significantly decreased in the colonic enterocytes from 
intestinal BD and IBD patients compared to control but also more decreased 
in those of BD with risk alleles than in those of BD without risk alleles. 
Indeed, these results were supported in inflamed colon by colitis in mice and 
LPS stimulation of intestinal epithelial cells reduced the expression of 
NAALADL2 and YIPF7 in vitro. SNPs in NAALADL2 contain characteristics 
of transcriptional regulatory activity directly impacting its expression. 
Concordantly, LPS reduced also the mRNA level of NAALADL2 both in vivo 
and in vitro. However, mRNA levels of YIPF7 were higher in colon of 
intestinal BD and IBD than in colon of control, while lower in inflamed colon 
tissues of mice than in colon tissues of control. It is possible that YIPF7 may 
be regulated post-transcriptional and translational regulation or caused by 
different pathophysiology of intestinal BD and IBD compared with animal 
model using chemical.
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Taken together, our results suggest that these genes are strong candidates 
for the causal variants of intestinal BD development.37, 38 Interestingly, HLA-
B*51 was associated with moderately higher prevalence of genital ulcers, 
ocular and skin manifestations, and a decreased prevalence of gastrointestinal 
involvement in BD39 in GWAS, whereas HLA-B*51 showed no relationship 
with IBD.40 Consistently, we found that PSORS1C1 gene loci in the HLA-B 
region showed significant association with BD without intestinal involvement 
through GWAS, replication, and haplotype studies. Moreover, PSORS1C1 is 
most significant associated loci with all BD consistent with previous BD 
study in Han Chinese in GWAS study,3, 6 whereas HLA-B did not in our study. 
Although HLA-B*51 is known as the most strongly associated genetic risk 
factor to BD in several populations,3, 4, 41 it accounts for less than 20% of the 
whole genetic risk.41 In addition, the independent genetic associations of 
HLA-B*51, PSORS1C1, and HLA-F-AS1 with BD reported in a previous 
study for fine mapping in the extended HLA region were consistent with our 
data3. Moreover, PSORS1C1 showed strongly association with HLA-B51 
positivity (OR: 56.39) and CNS lesions (aOR: 23.23), which is stronger 
interaction compared to interaction (OR: 3.78) between ERAP1 and HLA-
B*51 found in BD GWAS.2 The possible role of HLA-B*51 in BD may be 
the presentation of HLA-B*51-restricted peptides to CD8+ cells and the in 
inhibitory effect of HLA-B*51 binding to killer Ig-like receptor DL1 
(KIR3DL1) on NK cells,42, 43 although the exact clinical pictures of HLA-
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B*51-positive and negative BD are virtually indistinguishable and genotyping 
of this allele cannot accurately predict the occurrence of specific organ or 
system manifestations39 Taken together, our results suggest that PSORS1C1
genetic variation is associated with development of BD without intestinal 
involvement independently and regardless of HLA-B as previous study3 and 
made the strongest contribution to BD without intestinal involvement in our 
study. 
Among previously implicated loci of GWAS,4, 5 CCR1-CCR3, IL23R-
IL12RB2, HLA-F-AS1–HLA-A, and KLRC4-KLRK1 did not show a significant 
association with any subtypes of BD in our study. One of the main reasons 
might be that individual has a unique combination of factors involved in their 
disease development, GWAS does not take account of supporting evidence 
from more-complex patterns of associations with other polymorphisms in the 
same gene and the relatively modest sample size compromises power44 as well 
as other unknown variants in the region in high LD with the investigated loci 
may be altering the regulation of the protein expression, or influencing protein 
translation and degradation.45, 46 Hence, the analysis of functional anlysis and 
pathways may help further elucidate genetic factors in BD pathogenesis. IL10
and STAT4 polymorphisms were associated with BD development with > 
80% power before Bonferroni correction, which corresponds to other recent 
studies,5, 47 indicating that the conditions of our data set have statistically 
enough power. In addition, ERAP1 and ELMO1 showed modest evidence in 
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terms of susceptibility of intestinal BD and ERAP1 and ELMO1 was 
associated with intestinal perforation and intestinal fistula, respectively, which 
suggest that these genes may be related with severe disease phenotypes. 
Consistently, previsous studies implicated that ERAP1 are shared in 
inflammatory pathways in BD and spondyloarthritides48 and SNPs in ERAP1
showed association with Japanese CD patients.32 ELMO1 (engulfment and 
cell motility 1) promotes internalization of the dying cells through the ability 
to engulf and to clear apoptotic cells49. ERAP1 is a ubiquitous 
metallopeptidase that functions to trim cooperatively with ERAP2 antigenic 
peptide precursors for proper loading onto MHC class I molecules and 
ERAP1-deficient mice were less able to present self- and foreign antigens.50-52
rs17482078 and rs2927615 in ERAP1 showed possibly damaging in silico 
analysis and the regulatory function in eQTL analysis, respectively. 
Consistent with these results, non-synonymous coding variant rs17482078 
(p.Arg725Gln) confer protection against these diseases through reduced 
peptide trimming and antigen presentation by MHC class I molecules48 and 
recessively conferred the risk of disease with uveitis.2 eQTL analyses showed 
that rs2927615 in ERAP1, located in an evolutionary conserved sequence, not 
only down-regulates its own gene expression including STAT4 and 
PSORS1C1 but also up-regulates IL10 expression in company with SNPS in 
ELMO1 and DCAF12. Regulation of IL10 expression is of particular interest 
because it protects colonic inflammation in mice53-56 and as well as other 
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inflammatory diseases.57 SNPs of IL10 were shown to have more significant 
correlation with intestinal BD than BD without intestinal involvement in our 
replication and haplotype studies and correlation with down-regulation of its 
expression and increase of proinflammatory gene expression such as IL12RB2
and PSORS1C1 in eQTL analysis. The risk loci of intestinal BD (IL10) were 
shared with IBD,58-60 the other loci of BD without intestinal involvement 
(PSORS1C1) with psoriasis,61, 62 which implicates distinguishing and shared 
pathogenic pathways between BD and other autoimmune diseases as well as 
between intestinal BD and IBD. As support these results, the 13 replicated 
loci related to intestinal BD function in B lymphocytes and CXCR4, which is 
shared with BD without intestinal involvement, where the common variations 
in each of these genes have little correlation with disease risk. In addition, 
pathways of BD SNPs were overlapped with pathways of IBD SNPs, which 
may be also mediated by CEBPB and PLC molecules, pivotal functional 
molecules in both the common pathway and regulatory SNP. These results 
support that intestinal BD genes shows BD phenotypes or increase intestinal 
BD phenotypes through complex interactions with genes with BD without 
intestinal involvement as well as intestinal involvement. Because the 
combination of multiple variants with small effects explains the overall 
susceptibility to multifactorial diseases and cause the same disease phenotype 
in complex diseases, the disruption of different biological pathways is thought 
to determine the intrinsic biological processes of multifactorial diseases.27 In 
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this regard, these results are consistent with the studies reporting that variants 
in IL10 are also associated with ulcerative colitis (UC) and Crohn’s disease 
(CD) in infancy63, 64 and knockout mouse of Il10 is the best animal models of 
IBD, which suggest that there is a shared inherited susceptibility between BD, 
especially intestinal BD and IBD. In addition to implicating the association of 
IL10 with colon inflammation, pathway analysis showed networks beteen 
intestinal BD and IBD through IL10, IL12, and ERAP1. Consistently, our 
data showed that IL17 and IL12B were increased but IL10 reduced in 
inflammed colon tissues of intestinal BD and mice. It is known that key gene 
variants of the IL-12 and IL-23/Th17 pathway such as IL23R and STAT4. 
Similar to IL23R, IL12B as part of IL-23 is also a shared susceptibility gene 
with other IBD-associated diseases such as psoriasis65 and ankylosing 
spondylitis,66 providing an explanation of the increased incidence of these 
extraintestinal manifestations in IBD patients. Remarkably, the strongest 
cluster of common CD and UC susceptibility genes is formed by genes related 
to the IL-23/Th17 pathway including IL12B.14 potential epistasis between the 
main IBD susceptibility genes as major pathomechanism in the disease 
pathogenesis. The IL12B SNP rs6887695 modulates the susceptibility and the 
phenotype of IBD.67
Consistently, IL12B is regareded as established IBD susceptibility gene as 
well as IL23R.67 Biological pathway analyses in this study were in close 
agreement in emphasizing the crosstalk of general biological pathways 
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between intestinal BD and IBD or BD without intestinal involvement. 
Collectively, our finding strongly suggests a difference of pathway changes 
between intestinal BD and systemic BD, suggesting overlapping yet distinct 
genetic architectures for these two diseases. 
Furthermore, comparisons between intestinal BD and BD without intestinal 
involvement showed modest evidence for differences between the two 
conditions in CD180 (Lymphocyte antigen 64), PLCB1 (phospholipase C beta 
1), and TGFBR3 (transforming growth factor, beta receptor 3), although they 
failed to pass Bonferroni test in the replication study (Supporting information 
4). PLCB1, and TGFBR3 including DCAF12 (DDB1 and CUL4 associated 
factor 12), and SCHIP1 (schwannomin interacting protein 1) were also 
suggested to be potential causal variants in association with intestinal BD in 
haplotype analysis. CD180 is a cell surface molecule consisting of 
extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail. The 
extracellular LRR form the cell surface receptor complex, RP105/MD-1, 
which, by working in concert with toll-like receptors 4 (TLR4), controls B 
cell recognition and signaling of lipopolysaccharide (LPS).68 PLCB1 is the 
major nuclear PLC-β isozyme and its expression is increased in the 
proliferating crypt compartments of the intestine in mice.69 Interactions 
between the gut microbiota and epithelial cells trigger the increase of DUOX 
enzymatic activity via PLC-β-dependent production of inositol-1,4,5-
trisphosphate.70 TGFBR3 had SNP of eQTL (rs1805110) and regulatory SNP 
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(rs17882828) in our study. Risk alleles of TGFBR3 not only increase the 
expression of IL23R, IL12RB2, KLRC4, TGFB1 but also decrease the 
expression of IL10. While the polymorphisms in BD were reported in other 
groups,71, 72 TGFBR3 is also known to function in colon cancer.73, 74 DCAF12
revealed significant increase of proinflammatory gene expression such as 
CCR1, CCR3, TNF, IL5, IL13, ERAP1, NUDT275, 76 and decrease of IL10
expression in eQTL analyses.
V. CONCLUSION
Our study provides the first notable evidence that there are specific g
enetic susceptibility loci associated with intestinal involvement in BD pa
tients. We also found independet genetic variants associated with develo
pment of intestinal BD and BD without intestinal involvement, which s
howed a partial overlap with psoriasis or IBD. Of previously identified 
genes in GWAS of BD, PSORS1C1 seem to be responsible for BD wit
hout intestinal involvement and ERAP1, ELMO1, and IL10 to be more 
responsible for intestinal BD than for BD without intestinal involvement, 
which suggest that there are fundamentally shared pathogenic pathways 
between BD and psoriasis or between BD without intestinal involvement 
and IBD. Our GWAS results separating between intestinal BD and BD 
without intestinal involvement enable a more comprehensive analysis of 
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disease specificity and provide insight into the common and different pa
thogenic mechanisms for intestinal BD and IBD suggesting new therape
utic strategies, although further larger multi-center replicated studies and 
additional functional experiments are required to confirm our findings.
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<ABSTRACT (IN KOREAN)> 
유전체 전장 연관성 분석에 의한 베체트 장염의 감수성
유전자 발굴
<지도교수 천 재 희>
연세대학교 대학원 의학과
정 윤 숙
최근 몇몇 유전체 전장 연관성 분석 연구들에 의해서
베체트병과 염증성 장질환의 발생과 관련이 있는 유전자들이
밝혀지고 있다. 하지만 현재까지 베체트 장염의 발생과 관련
있는 유전자들에 대한 연구는 시행된 바가 없다. 본
연구에서는 유전체 전장 연관성 분석을 통하여 베체트 장염의
감수성 유전자를 조사하였다.
  100명의 장질환 침범이 없는 베체트병군과 99명의
베체트 장염군, 그리고 557명의 정상 대조군을 대상으로
유전체 전장 연관성 분석을 시행하였다. 새로운 코호트인
138명의 장질환 침범이 없는 베체트병군과 196명의 베체트
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장염군을 대상으로 후보 유전자들 변이를 검증하였다
(validation study). 또한 후보 유전자들의 단백질 발현을
평가하기 위해 면역조직화학 염색을 시행하였다.  
유전체 전장 연관성 분석과 검증 연구 (validation study) 를
통해 NAALADL2 (rs3914501, OR = 1.914, P = 3.5 × 10−4 
in a recessive model) 유전자가 베체트 장염의 감수성
유전자임을 확인할 수 있었다. 또한 NAALADL2 유전자는
베체트 장염의 발생뿐만 아니라 누적 수술률, 입원률, 
스테로이드 사용률과도 관련이 있어 나쁜 예후와도 연관성이
있었다. ERAP1 유전자와 IL10 유전자 역시 베체트 장염의
발생과 연관성이 있었다. 한편, 장질환 침범이 없는
베체트병군과 베체트 장염군간의 비교 분석 결과, YIPF7
(rs6838327, OR = 1.522, P = 5.6 × 10−4) 유전자 변이가
의미있게 차이가 있었다. 장질환 침범이 없는 베체트병의
감수성 유전자는 이미 기존 연구에서 베체트병과 관련성이
보고된 바 있는 PSORS1C1 (rs12525170, OR = 2.210, P = 
1.1 × 10−5) 유전자임 확인할 수 있었다. 
결론적으로 본 연구를 통해 세계 최초로 베체트 장염의
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감수성 유전자들을 발굴할 수 있었다. 이런 발굴된 유전자들
일부는 염증성 장질환이나 다른 자가 면역 질환들과도
연관성이 보고된 바 있다. 본 연구 결과들은 베체트 장염이
다른 자가 면역 질환들과 구별되는 유전적 특징을 가지고
있을 뿐 아니라 염증성 징질환이나 다른 자가 면역질환과
유전적으로 공유되는 특징도 가지고 있음을 시사한다. 
----------------------------------------------
핵심되는 말 : 베체트 장염, 유전체 전장 연관성 분석 연구, 
질병 감수성 유전자
